MAP4K2 Antikörper (AA 386-469) (FITC)

Produktnummer ABIN7160067

Produktdetails anti-MAP4K2 Antikörper (FITC)

Target: MAP4K2 (Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2))

Bindungsspezifität: AA 386-469

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser MAP4K2 Antikörper ist konjugiert mit FITC

Applikation: Bitte anfragen

Kreuzreaktivität: Human

Aufreinigung: >95%, Protein G purified

Immunogen: Recombinant Human Mitogen-activated protein kinase kinase kinase kinase 2 protein (386-469AA)

Isotyp: IgG

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu MAP4K2

Target: MAP4K2 (Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2))

Andere Bezeichnung: MAP4K2 (MAP4K2 Produkte)

Synonyme: BL44 antikoerper, GCK antikoerper, RAB8IP antikoerper, AI385662 antikoerper, Rab8ip antikoerper, MAP4K2 antikoerper, dZ150L22.2 antikoerper, map4k2l antikoerper, map4k2l-2 antikoerper, map4k3l antikoerper, si:dz150l22.2 antikoerper, si:dz263j20.1 antikoerper, zgc:136670 antikoerper, mitogen-activated protein kinase kinase kinase kinase 2 antikoerper, mitogen activated protein kinase kinase kinase kinase 2 antikoerper, MAP4K2 antikoerper, Map4k2 antikoerper, LOC103346779 antikoerper, map4k2 antikoerper

Hintergrund:

Background: Serine/threonine-protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Acts as a MAPK kinase kinase kinase (MAP4K) and is an upstream activator of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway and to a lesser extent of the p38 MAPKs signaling pathway. Required for the efficient activation of JNKs by TRAF6-dependent stimuli, including pathogen-associated molecular patterns (PAMPs) such as polyinosine-polycytidine (poly(IC)), lipopolysaccharides (LPS), lipid A, peptidoglycan (PGN), or bacterial flagellin. To a lesser degree, IL-1 and engagement of CD40 also stimulate MAP4K2-mediated JNKs activation. The requirement for MAP4K2/GCK is most pronounced for LPS signaling, and extends to LPS stimulation of c-Jun phosphorylation and induction of IL-8. Enhances MAP3K1 oligomerization, which may relieve N-terminal mediated MAP3K1 autoinhibition and lead to activation following autophosphorylation. Mediates also the SAP/JNK signaling pathway and the p38 MAPKs signaling pathway through activation of the MAP3Ks MAP3K10/MLK2 and MAP3K11/MLK3. May play a role in the regulation of vesicle targeting or fusion. regulation of vesicle targeting or fusion.

Aliases: B lymphocyte serine/threonine protein kinase antibody, B lymphocyte serine/threonine-protein kinase antibody, BL44 antibody, GC kinase antibody, GCK antibody, Germinal center kinase antibody, germinal centre kinase (GC kinase) antibody, M4K2_HUMAN antibody, Map4k2 antibody, MAPK/ERK kinase kinase kinase 2 antibody, MEK kinase kinase 2 antibody, MEKKK 2 antibody, Mitogen activated protein kinase kinase kinase kinase 2 antibody, Mitogen-activated protein kinase kinase kinase kinase 2 antibody, Rab8 interacting protein antibody, Rab8 interacting protein, formerly antibody, Rab8-interacting protein antibody, RAB8IP antibody, RAB8IP, formerly antibody

UniProt: Q12851